Compare BioNano Genomics Inc (BNGO) vs Kroger Co (KR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Kroger Co — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.20M), while Kroger Co trades at $58.7 (market cap $35.99B). The key difference: Kroger Co is far larger — about 2726.5× BioNano Genomics Inc's market cap, and Kroger Co pays a 2.45% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | KR | |
|---|---|---|
Market Cap | $13.20M | $35.99B |
Sector | Health | Consumer Staples |
52-Week High | $4.92 | $75.60 |
52-Week Low | $1.09 | $55.53 |
Enterprise Value | $15.81M | $56.08B |
Dividend Yield | — | 2.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Kroger (KR) trades at $59.31, down 2.03% today, with technical indicators showing bearish momentum. The company maintains stable revenue around $147B with improving net margins (1.81% in 2025) and recently announced a $1.65B acquisition of Giant Eagle to expand Midwest presence. Strong cash flow generation ($2.08B net in 2025) supports dividend payments and strategic investments.
Kroger presents a mixed outlook with attractive valuation metrics (P/S 0.26) and analyst consensus target of $68.63 offering 16% upside potential. However, competitive pressures, recent earnings miss, and bearish technical signals warrant caution. The Giant Eagle acquisition provides growth opportunity but integration risks remain.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →
